[1. Altayli E. et al.: Prevention and treatment of cyclophosphamide and ifosfamide-induced hemorrhagic cystitis. J. Mol. Pathophysiol., 1, 53, 2012.10.5455/jmp.20120321060902]Search in Google Scholar
[2. Benarroch E.E.: Autonomic-mediated immunomodulation and potential clinical relevance. Neurology, 73, 236, 2009.10.1212/WNL.0b013e3181aebd43]Search in Google Scholar
[3. Bouchelouche K. et al.: Increased urinary leukotriene E4 and eosinophil protein X excretion in patients with interstitial cystitis. J. Urol., 166, 2121, 2001.10.1016/S0022-5347(05)65518-8]Search in Google Scholar
[4. Bouchelouche K. et al.: The action of cysteinyl-leukotrienes on intracelluar calcium mobilization in human detrusor myocytes. BJU Int., 87, 690, 2001.10.1046/j.1464-410x.2001.02135.x]Search in Google Scholar
[5. Bouchelouche K. et al.: The cysteinyl leukotriene D4 receptor antagonist montelukast fort the treatment of interstitial cystitis. J. Urol., 166, 1734, 2001.10.1016/S0022-5347(05)65663-7]Search in Google Scholar
[6. Chuang Y.C. et al.: Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and supresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur. Urol., 56, 159, 2009.10.1016/j.eururo.2008.05.00718514386]Search in Google Scholar
[7. Dobrek Ł., Baranowska A., Thor P.J.: The inf luence of oxazaphosphorines alkylating agents on autonomic nervous system activity in rat experimental cystitis model. Acta Pol. Pharm., 70, 1097, 2013.]Search in Google Scholar
[8. Dobrek Ł., Thor P.: Heart rate variability in overactive bladder experimental model. Arch. Med. Sci., 9, 930, 2013.]Search in Google Scholar
[9. Dobrek Ł., Thor P.J.: Bladder urotoxicity pathophysiology induced by the oxazaphosphorine alkylating agents and ist chemoprevention. Postepy Hig. Med. Dosw. (online), 66, 592, 2012.]Search in Google Scholar
[10. Girard B.M. et al.: Increased expression of interleukin-6 family members and receptors in urinary bladder with cyclophosphamideinduced bladder inflammation in female rats. Front. Neurosci., 5, article 20, 2011.10.3389/fnins.2011.00020304455921373362]Search in Google Scholar
[11. Goncalves H. et al.: Analysis of heart rate variability in a rat model of induced pulmonary hypertension. Med. Eng. Phys., 32, 746, 2010.10.1016/j.medengphy.2010.04.01820547091]Search in Google Scholar
[12. Grover S. et al.: Role of inflammation in bladder function and interstitial cystitis. Ther. Adv. Urol., 3, 19, 2011.10.1177/1756287211398255312608821789096]Search in Google Scholar
[13. Haeggstrom J.Z., Funk C.D.: Lipooxygenase and leukotriene pathways: biochemistry, biology and roles in disease. Chem. Rev., 111, 5866, 2011.]Search in Google Scholar
[14. Huston J.M., Tracey K.J.: The pulse of inflammation: heart rate variability, the cholinergic anti-inf lammatory pathway and implications for therapy. J. Intern. Med., 269, 45, 2011.]Search in Google Scholar
[15. Karim N, Hasan JA, Ali SS. Heart rate variability - a review. J. Basic Appl. Sci., 7, 71, 2011.]Search in Google Scholar
[16. Lampert R. et al. : Decreased heart rate variability is associated with higher levels of inflammation in middle-aged men. Am. Heart J., 156, 759e1, 2008.10.1016/j.ahj.2008.07.009258793218926158]Search in Google Scholar
[17. Lanza,G.A. et al.: Relation of heart rate variability to serum levels of C reactive protein in patients with unstable angina pectoris. Am. J. Cardiol., 97,1702, 2006.]Search in Google Scholar
[18. Lee G., Romih R., Zupancic D.: Cystitis: from urothelial cell biology to clinical application. Biomed. Res. Int., article ID 473536, 2014.10.1155/2014/473536402211324877098]Search in Google Scholar
[19. Mohamadin A.M. et al.: Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver. Pathophysiology, 18, 235, 2011.]Search in Google Scholar
[20. Mukherjee N. et al.: Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice. PLoS ONE, 8, e61607, 2013.10.1371/journal.pone.0061607363401923626702]Search in Google Scholar
[21. Nicolini A. et al.: Malnutrition, anorexia and cachexia in cancer patients: a mini review on pathogenesis and treatment. Biomed. Pharmacother., 67, 807, 2013.]Search in Google Scholar
[22. No Authors listed. Heart rate variability. Standards of measurement, physiological interpretation and clinical use. Task Force of The European Society of Cardiology and The North American Society of Pacing and Electrophysiology. Eur. Heart J., 17, 354, 1996.]Search in Google Scholar
[23. Papaioannou V., Pneumatikos I., Maglaveras N.: Association of heart rate variability and inflammatory response in patients with cardiovascular diseases: current strengths and limitations. Front. Physiol., 4, 174, 2013.]Search in Google Scholar
[24. Rahnama’i M.S., van Koevringe G.A., van Kerrebroeck P.E.: Overactive bladder symptom and the potential role of prostaglandins and phosphodiesterases: an introduction. Nephro. Urol. Mon., 5, 933, 2013.]Search in Google Scholar
[25. Sztajzel J.: Heart rate variability: a noninvasive electrocardiographic method to measure the autonomic nervous system. Swiss. Med. Wkly. 134, 514, 2004.]Search in Google Scholar
[26. Tintinger G.R. et al.: Montelukast: more than a cysteinyl leukotriene receptor antagonist? ScientificWorldJournal, 10, 2403, 2010.10.1100/tsw.2010.229576394121170491]Search in Google Scholar
[27. Traut J.L. et al.: Montelukast for symptom control of interstitial cystitis. Ann. Pharmacother., 45, e49, 2011.10.1345/aph.1Q13021862713]Search in Google Scholar
[28. Zeng J. et al.: Cause of residual urine in bladder outlet obstruction: an experimental study in the rat. J. Urol., 188, 1027, 2012. 10.1016/j.juro.2012.04.10122819110]Search in Google Scholar